HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Enlivex Therapeutics (NASDAQ:ENLV) and maintained a $15 price target.
August 01, 2023 | 10:21 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enlivex Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $15.
The reiteration of a 'Buy' rating and maintained price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. This could potentially lead to an increase in the stock's demand and subsequently its price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100